Sunitinib malate for the treatment of solid tumours: a review of current clinical data

The biology of VEGF and its receptors

2003 • 9,272 citations

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

2002 • 5,914 citations

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

2002 • 4,254 citations

Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis

2004 • 2,891 citations

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

2003 • 2,723 citations

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

2003 • 2,216 citations

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

2003 • 1,939 citations

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

2005 • 1,630 citations

Rising Incidence of Renal Cell Cancer in the United States

1999 • 1,593 citations

Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

2002 • 1,471 citations

The role of pericytes in blood-vessel formation and maintenance

2005 • 1,437 citations

Tyrosine Kinases as Targets for Cancer Therapy

2005 • 1,365 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,236 citations

Biology of Gastrointestinal Stromal Tumors

2004 • 1,190 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,172 citations

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

2005 • 1,140 citations

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

2003 • 860 citations

The role of FLT3 in haematopoietic malignancies

2003 • 831 citations

PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

2005 • 809 citations

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

2003 • 766 citations

Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.

2001 • 648 citations

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

2003 • 634 citations

Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms

2003 • 598 citations

PDGF receptors as cancer drug targets

2003 • 462 citations

Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma

2004 • 408 citations

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

2003 • 380 citations

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

2003 • 305 citations

The RET proto-oncogene in human cancers

2000 • 295 citations

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

2005 • 280 citations

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1998 • 271 citations

SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.

2003 • 262 citations

Gastrointestinal Stromal Tumors in Children and Young Adults

2005 • 258 citations

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

2003 • 252 citations

Novel approaches in the therapy of metastatic renal cell carcinoma

2005 • 222 citations

Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.

2001 • 214 citations

Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis.

1995 • 195 citations

Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

2003 • 182 citations

Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops

1998 • 175 citations

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

2006 • 134 citations

Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy

2005 • 125 citations

Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)

2005 • 120 citations

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST

2005 • 119 citations

Autoinhibition Control

2003 • 118 citations

Expression of Growth Factor Peptides and Their Receptors in Neuroendocrine Tumors of the Digestive System

1993 • 115 citations

The Role of CSF-1 in Normal Physiology of Mammary Gland and Breast Cancer: An Update

2004 • 106 citations

Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?

1999 • 91 citations

A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)

2005 • 76 citations

Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)

2005 • 75 citations

Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs)

2005 • 73 citations

State-of-the Art Therapy for Gastrointestinal Stromal Tumors

2005 • 72 citations

Targeted therapies for non–small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective

2004 • 63 citations

Su-11248 Sugen.

2004 • 58 citations

Chemotherapy in metastatic renal cell cancer

2005 • 56 citations

Immunotherapy in metastatic renal cell carcinoma

2005 • 36 citations

Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib

2004 • 29 citations

Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers

2005 • 22 citations

88th Annual Meeting of the American Association for Cancer Research

1997 • 12 citations

797 ORAL Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials

2005 • 4 citations

1456 POSTER Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248)

2005 • 1 citations